市場調査レポート

生物兵器防衛市場分析:製品別 (炭疽菌、天然痘、ボツリヌス中毒、放射線/核、エボラ、出血熱) 、セグメント別の予測

Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear, Ebola, Hemorrhagic Fever) And Segment Forecasts To 2020

発行 Grand View Research, Inc. 商品コード 342329
出版日 ページ情報 英文 80 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
生物兵器防衛市場分析:製品別 (炭疽菌、天然痘、ボツリヌス中毒、放射線/核、エボラ、出血熱) 、セグメント別の予測 Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear, Ebola, Hemorrhagic Fever) And Segment Forecasts To 2020
出版日: 2015年01月01日 ページ情報: 英文 80 Pages
概要

世界の生物兵器防衛市場は、2020年までに133億3千万米ドルに達すると見込まれています。バイオテロの脅威、病気の蔓延に加えて、バイオテクノロジー分野への研究開発投資の増加が、市場成長を後押しすると予測されています。

当レポートでは、世界の生物兵器防衛市場に調査分析し、製品別、地域別の見通しのほか、主要企業について、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 生物兵器防衛産業の見通し

  • 市場区分
  • 市場規模と成長見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 優先される主要機会
  • PESTEL分析
  • 市場シナリオ:種類別

第3章 生物兵器防衛の製品別の見通し

  • 製品別
  • 炭疽菌
  • 天然痘
  • ボツリヌス中毒
  • 放射線/核防衛
  • その他

第4章 生物兵器防衛の地域別の見通し

  • 地域別
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
  • アジア太平洋地域
    • 日本
    • 中国
  • その他

第5章 競合情勢

  • 企業プロファイル (企業概要、財務実績、製品ベンチマーク、戦略的構想)
    • Xoma Corporation
    • PharmAthene
    • Emergent Biosolutions
    • Dynavax Technologies Inc.
    • SIGA Technologies
    • Elusys Therapeutics
    • Ichor Medical Systems Inc.
    • DynPort Vaccine Company LLC
    • Cleveland BioLabs, Inc.
    • Bavarian Nordic
    • Achaogen
    • Nanotherapeutics, Inc.
    • Alnylam Pharmaceuticals

第6章 調査手法と範囲

図表

目次

Global biodefense market is expected to reach USD 13.33 billion by 2020. Growing R&D investments in the field of biotechnology coupled with increasing threat of bioterrorism and disease outbreaks is expected to drive market growth during the forecast period. Furthermore, presence of favorable government initiatives for instance the Emergency Use Authorization (EUA) is expected to boost market growth. This provision allows products to be marketed without an FDA approval in an emergency. Initiatives undertaken by the governments of developing nations for strengthening their respective biodefense product portfolio is expected to fuel future market growth.

Biodefense against anthrax accounted for the largest market share owing to its inclusion in the class A highest priority pathogen category. This classification has resulted in the presence of extensive R&D investments aimed at new product development for strengthening national stockpiles. The global biodefense against anthrax was valued at over USD 2.0 billion in 2013.

Further key findings from the study suggest:

North American was the most revenue generating region in 2013. Majority of the funding programs are organized by the U.S. based government and private establishments. Moreover, these establishments cater to procurement needs of foreign markets.

The market is majorly governed by the initiatives undertaken in the U.S. The country is the largest revenue contributor and is expected to maintain its market position throughout the forecast period. Moreover, funding received by manufacturers under projects such as BioShield is expected to significantly boost demand over the next six years.

Developed European countries such as Germany and the UK have designated funding policies in place pertaining to biodefense. In Switzerland, there is no set biodefense definition but the NBC (nuclear, biological, chemical) protection and research is carried out in Spiez Laboratory of Federal office for Civil Protection, within the Federal Department of Defense. A total of 12 civilian facilities operate under the Swiss biodefense program.

Key players of this market include Emergent BioSolutions, SIGA Technologies, Xoma Corporation and PharmAthene.

Mergers and acquisitions and participating in government tenders are two key sustainability strategies adopted by market players. For instance, in December, 2014, Emergent BioSolutions announced that it had acquired the EV-035 series of molecules from Evolva Holding SA. The acquisition will further strengthen the company's biodefense line of products.

For the purpose of this study, Grand View Research has segmented the global biodefense market on the basis of product and region:

Global Biodefense Product Outlook (Revenue, USD Million, 2012 - 2020)

  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/Nuclear defense
  • Others

Biodefense Regional Outlook (Revenue, USD Million, 2012 - 2020)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • Japan
    • China
  • RoW
    • Brazil

Table of Contents

Chapter 1: Executive Summary

Chapter 2: Biodefense Industry Outlook

  • 2.1. Market Segmentation
  • 2.2. Market size and growth prospects
  • 2.3. Biodefense-Market dynamics
    • 2.3.1. Market driver analysis
      • 2.3.1.1. Presence of favorable government initiatives
      • 2.3.1.1.1. Emergency Use Authorization of Medical Products
      • 2.3.1.1.2. Project BioShield Act
    • 2.3.2. Market Restraint Analysis
      • 2.3.2.1. Low market penetration in developing and underdeveloped countries
  • 2.4. Key Opportunities Prioritized
  • 2.6. Biodefense-PESTEL analysis
  • 2.7. Market scenario by type
    • 2.7.1. Biological Defense
    • 2.7.2. Chemical Defense
      • 2.7.2.1. Chemical defense: Product pipeline
    • 2.7.3. Nuclear/Radiological Defense
      • 2.7.3.1. Nuclear/radiological defense: Product pipeline analysis

Chapter 3: Biodefense Product Outlook

  • 3.1. Biodefense market share by product, 2013 & 2020
  • 3.2. Anthrax
    • 3.2.1. Biodefense against anthrax market, 2012-2020(USD Million)
  • 3.3. Smallpox
    • 3.3.1. Biodefense against smallpox market, 2012-2020(USD Million)
  • 3.4. Botulism
    • 3.4.1. Biodefense against botulism market, 2012-2020(USD Million)
  • 3.5. Radiation/ nuclear defense
    • 3.5.1. Biodefense against radiation/nuclear defense market, 2012-2020(USD Million)
  • 3.6. Others
    • 3.6.1. Biodefense against other threats market, 2012-2020(USD Million)

Chapter 4: Biodefense Regional Outlook

  • 4.1. Biodefense market share by region, 2013 & 2020
  • 4.2. North America
    • 4.2.1. North America biodefense market, 2012-2020(USD Million)
    • 4.2.2. U.S. biodefense market, 2012-2020(USD Million)
    • 4.2.3. U.S. biodefense market,2012-2020(USD Million)
      • 4.2.3.1. U.S. biodefense market, by scenario, 2012-2020(USD Million)
    • 4.2.4. U.S. biodefense market, by source, 2012-2020(USD Million)
      • 4.2.4.1. Federal Agencies
      • 4.2.4.1.1. BioShield Act
      • 4.2.4.1.2. Department of Health and Human Services(HHS)
      • 4.2.4.1.3. Department of Defense(DoD)
      • 4.2.4.1.4. Department of Homeland Security
      • 4.2.4.1.5. Department of Agriculture
      • 4.2.4.1.6. Environmental Protection Agency
      • 4.2.4.1.7. Department of Commerce
      • 4.2.4.2. Other Agencies
    • 4.2.5. Canada biodefense market, 2012-2020(USD Million)
  • 4.3. Europe
    • 4.3.1. Europe biodefense market, 2012-2020(USD Million)
    • 4.3.2. Germany biodefense market, by product,2012-2020(USD Million)
    • 4.3.3. Germany biodefense market, 2012-2020(USD Million)
    • 4.3.4. UK biodefense market, by product, 2012-2020(USD Million)
    • 4.3.5. UK biodefense market, 2012-2020(USD Million)
  • 4.4. Asia Pacific
    • 4.4.1. Asia Pacific biodefense market, 2012-2020(USD Million)
    • 4.4.2. Japan biodefense market, 2012-2020(USD Million)
    • 4.4.3. Japan biodefense market, 2012-2020(USD Million)
    • 4.4.4. China biodefense market, 2012-2020(USD Million)
  • 4.5. RoW
    • 4.5.1. RoW biodefense market, 2012-2020(USD Million)

Chapter 5: Competitive Landscape

  • 5.1. Xoma Corporation
    • 5.1.1. Company Overview
    • 5.1.2. Financial Performance
    • 5.1.3. Product Benchmarking
    • 5.1.4. Strategic Initiatives
  • 5.2. PharmAthene
    • 5.2.1. Company Overview
    • 5.2.2. Financial Performance
    • 5.2.3. Product Benchmarking
    • 5.2.4. Strategic Initiatives
  • 5.3. Emergent Biosolutions
    • 5.3.1. Company Overview
    • 5.3.2. Financial Performance
    • 5.3.3. Product Benchmarking
    • 5.3.4. Strategic Initiatives
  • 5.4. Dynavax Technologies Inc.
    • 5.4.1. Company Overview
    • 5.4.2. Financial Performance
    • 5.4.3. Product Benchmarking
    • 5.4.4. Strategic Initiatives
  • 5.5. SIGA Technologies
    • 5.5.1. Company Overview
    • 5.5.2. Financial Performance
    • 5.5.3. Product Benchmarking
    • 5.5.4. Strategic Initiatives
  • 5.6. Elusys Therapeutics
    • 5.6.1. Company Overview
    • 5.6.2. Financial Performance
    • 5.6.3. Product Benchmarking
    • 5.6.4. Strategic Initiatives
  • 5.7. Ichor Medical Systems Inc.
    • 5.7.1. Company Overview
    • 5.7.2. Financial Performance
    • 5.7.3. Product Benchmarking
    • 5.7.4. Strategic Initiatives
  • 5.8. DynPort Vaccine Company LLC
    • 5.8.1. Company Overview
    • 5.8.2. Financial Performance
    • 5.8.3. Product Benchmarking
    • 5.8.4. Strategic Initiatives
  • 5.9. Cleveland BioLabs, Inc.
    • 5.9.1. Company Overview
    • 5.9.2. Financial Performance
    • 5.9.3. Product Benchmarking
    • 5.9.4. Strategic Initiatives
  • 5.10. Bavarian Nordic
    • 5.10.1. Company Overview
    • 5.10.2. Financial Performance
    • 5.10.3. Product Benchmarking
    • 5.10.4. Strategic Initiatives
  • 5.11. Achaogen
    • 5.11.1. Company Overview
    • 5.11.2. Financial Performance
    • 5.11.3. Product Benchmarking
    • 5.11.4. Strategic Initiatives
  • 5.12. Nanotherapeutics, Inc.
    • 5.12.1. Company Overview
    • 5.12.2. Financial Performance
    • 5.12.3. Product Benchmarking
    • 5.12.4. Strategic Initiatives
  • 5.13. Alnylam Pharmaceuticals
    • 5.13.1. Company Overview
    • 5.13.2. Financial Performance
    • 5.13.3. Product Benchmarking
  • 5.14. Major list of biodefense contracts, by market player

Chapter 6: Methodology and Scope

  • 6.1. Research Methodology
  • 6.2. Research Scope & Assumptions
  • 6.3. List of Data Sources

List of Tables

  • TABLE 1: Biodefense Market - Industry Summary & Critical Success Factors (CSFs)
  • TABLE 2: Biodefense market, by region, 2012 - 2020 (USD Million)
  • TABLE 3: U.S. biodefense market, by product, 2012 - 2020 (USD million)
  • TABLE 4: Biodefense - Key market driver analysis
  • TABLE 5: Biodefense - Key market restraint analysis
  • TABLE 6: Biological defense: Product pipeline
  • TABLE 7: List of pipeline products: Anthrax
  • TABLE 8: List of pipeline products: Smallpox
  • TABLE 9: List of pipeline products: Botulism
  • TABLE 10: List of pipeline products: Radiation/nuclear defense
  • TABLE 11: List of pipeline products: Other threats
  • TABLE 12: U.S. biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 13: U.S. biodefense market, by scenario, 2012 - 2020 (USD Million)
  • TABLE 14: U.S. biodefense market, by source, 2012 - 2020 (USD Million)
  • TABLE 15: Programs under HHS:
  • TABLE 16: Programs under DoD:
  • TABLE 17: Programs under department of homeland security
  • TABLE 18: Programs under department of agriculture
  • TABLE 19: Canada biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 20: Germany biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 21: Biodefense program licensed manufacturing sites in the UK
  • TABLE 22: UK biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 23: Japan biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 24: China biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 25: RoW biodefense market, by product, 2012 - 2020 (USD Million)
  • TABLE 26: Major list of biodefense contracts, by market player

List of Figures

  • FIG. 1: Biodefense: Market segmentation
  • FIG. 2: Global biodefense market, 2012 - 2020 (USD Million)
  • FIG. 3: Biodefense: Market dynamics
  • FIG. 4: Key opportunities prioritized
  • FIG. 5: Biodefense market - Porter's analysis
  • FIG. 6: Biodefense market - PESTEL analysis
  • FIG. 7: Biodefense market share by product, 2013 & 2020
  • FIG. 8: Global anthrax biodefense market, 2012 - 2020 (USD Million)
  • FIG. 9: Global smallpox biodefense market, 2012 - 2020 (USD Million)
  • FIG. 10: Global botulism biodefense market, 2012 - 2020 (USD Million)
  • FIG. 11: Global radiation/nuclear defense market, 2012 - 2020 (USD Million)
  • FIG. 12: Global biodefense market for other threats, 2012 - 2020 (USD Million)
  • FIG. 13: Biodefense market share by region, 2013 & 2020
  • FIG. 14: North America biodefense market , 2012 - 2020 (USD Million)
  • FIG. 15: U.S. biodefense market , 2012 - 2020 (USD Million)
  • FIG. 16: Canada biodefense market , 2012 - 2020 (USD Million)
  • FIG. 17: Europe biodefense market , 2012 - 2020 (USD Million)
  • FIG. 18: Germany biodefense market , 2012 - 2020 (USD Million)
  • FIG. 19: UK biodefense market , 2012 - 2020 (USD Million)
  • FIG. 20: Asia Pacific biodefense market , 2012 - 2020 (USD Million)
  • FIG. 21: Japan biodefense market , 2012 - 2020 (USD Million)
  • FIG. 22: China biodefense market , 2012 - 2020 (USD Million)
  • FIG. 23: RoW biodefense market , 2012 - 2020 (USD Million)
Back to Top